Reply to Ensina et al

Pediatr Allergy Immunol. 2018 Sep;29(6):670-671. doi: 10.1111/pai.12963.

Authors

Maria-Magdalena Balp¹, Karsten Weller², Veruska Carboni³, Alexandra Chirilov⁴, Charis Papavassilis¹, Thomas Severin¹, Haijun Tian⁵, Torsten Zuberbier², Marcus Maurer²

Affiliations

¹ Novartis Pharma AG, Basel, Switzerland.
² Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
³ GfK Switzerland AG, Risch-Rotkreuz, Switzerland.
⁴ GfK SE, Nuremberg, Germany.
⁵ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

PMID: 30054937
DOI: 10.1111/pai.12963

No abstract available

Publication types

Letter
Comment

MeSH terms

Child
Humans
Prevalence
Urticaria*